Carisoprodol Tablet
Product Images NDC 52536-682
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Carisoprodol (NDC 52536-682). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Wilshire Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (250 mg Tablet Bottle Label)
NDC 52536-682-10 is a labeled product containing tablets, USP with Carisoprodol, USP 250 mg as an active ingredient. The usual adult dosage is one tablet three times daily and at bedtime. The package insert must be seen for full prescribing information. The medicine should be dispensed in a tight, light-resistant container with a child-resistant closure. It should be stored at 20° to 25°C and kept out of the reach of children. The product is manufactured for Wilshire Pharmaceuticals, Inc. in Atlanta, GA 30328, and is a product of India. The remaining digits appear to be code numbers for identification purposes.*
Principal Display Panel (350 mg Tablet Bottle Label)
This is a description of Carisoprodol tablets, USP. Each tablet contains 350mg of Carisoprodol, USP. The usual adult dosage is one tablet three times daily and at bedtime. The medication must be dispensed in a tight, light-resistant container as defined in the USP using a child-resistant closure. The medication must be kept out of reach of children and stored at 20° to 25°C (68° to 77°F). This product is manufactured for Wilshire Pharmaceuticals, Inc. and is a product of India. The GTIN, YN, Code No., EXP, and LOT are also provided on the product label.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.